Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders

Psychological Medicine

Volumn 34, Issue 1, 2004, Pages 19-35

  Issakidis, Cathy ^a,b   Sanderson, K ^a   Corry, J ^a   Andrews, G ^a   Lapsley, H ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

AGORAPHOBIA; ANXIETY DISORDER; ARTICLE; BEHAVIOR THERAPY; CALCULATION; COGNITIVE THERAPY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; GENERALIZED ANXIETY DISORDER; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH SURVEY; MENTAL HEALTH CARE; MODEL; OBSESSIVE COMPULSIVE DISORDER; OUTCOMES RESEARCH; PANIC; POSTTRAUMATIC STRESS DISORDER; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SOCIAL PHOBIA; WELLBEING;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; AUSTRALIA; COGNITIVE THERAPY; COST OF ILLNESS; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; HEALTH CARE COSTS; HUMANS; MENTAL HEALTH SERVICES; MODELS, ECONOMETRIC; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS;

EID: 0942266233     PISSN: 00332917     EISSN: None     Source Type: Journal    
DOI: 10.1017/S003329170300881X     Document Type: Article

References (73)

1. Andrews, G. & Slade, T. (2002). Agoraphobia without a history of panic disorder is part of the panic disorder with or without agoraphobia syndrome. Journal of Nervous and Mental Disease 190, 624-630.
2. Andrews, G., Sanderson, K., Corry, J. & Lapsley, H. M. (2000). Using epidemiological data to model efficiency in reducing the burden of depression. Journal of Mental Health Policy, and Economics 3, 175-186.
3. Andrews, G., Henderson, A. S. & Hall, W. (2001a). Prevalence, comorbidity, disability and service utilisation. Overview of the Australian National Mental Health Survey. British Journal of Psychiatry 178, 145-153.
4. Andrews, G., Issakidis, C. & Carter, G. (2001b). Shortfall in mental health service utilisation. British Journal of Psychiatry 179, 417-425.
5. Andrews, G., Creamer, M., Crino, R., Hunt, C., Lampe, L. & Page, A. (2002a). The Treatment of Anxiety Disorders: Clinician's Guide and Patient Manuals, 2nd edn Cambridge University Press: Cambridge.
6. Andrews, G., Slade, T. & Issakidis, C. (2002b). Deconstructing current comorbidity: data from the Australian National Survey or Mental Health and Wellbeing. British Journal of Psychiatry 178, 306-314.
7. Andrews, G., Sanderson, K., Corry, J., Issakidis, C. & Lapsley, H. M. (2003). The cost effectiveness of current and optimal treatment for schizophrenia: evidence-based medicine is affordable. British Journal of Psychiatry 183, 427-435.
8. Ballenger, J. C., Davidson, J. R., Lecrubier, Y., Nutt, D. J., Borkovec, T. D., Rickels, K., Stein, D. J. & Wittchen, H. U. (2001). Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. Journal of Clinical Psychiatry 62 (suppl. 11), 53-58.
9. Bebbington, P. E., Meltzer, H., Brugha, T. S., Farrell, M., Jenkins, R., Ceresa, C. & Lewis, G. (2000a). Unequal access and unmet need: neurotic disorders and the use of primary care services. Psychological Medicine 30, 1359-1367.
10. Bebbington, P. E., Brugha, T. S., Meltzer, H., Jenkins, R., Ceresa, C., Farrell, M. & Lewis, G. (2000b). Neurotic disorders and the receipt of psychiatric treatment. Psychological Medicine 30, 1369-1376.
11. Bower, P., Richards, D. & Lovell, K. (2001). The clinical and cost-effectiveness of self-help treatments for anxiety and depressive disorders in primary care: a systematic review. British Journal of General Practice 51, 838-845.
12. Buckingham, B., Burgess, P., Solomon, S., Pirkis, J. & Eagar, K. (1998). Developing a Casemix Classification for Mental Health Services. Volume 1: Main Report. Commonwealth Department of Health and Family Services: Canberra.
13. Chancellor, J. V. M., Coyle, D. & Drummond, M. F. (1997). Constructing health state preference values from descriptive quality of life outcomes: mission impossible? Quality of Life Research 6, 159-168.
14. Commonwealth Department of Health and Aged Care (1999). Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners. Commonwealth of Australia: Canberra.
15. Coplan, J. D., Tiffon, L. & Gorman, J. M. (1993). Therapeutic strategies for the patient with treatment-resistant anxiety. Journal of Clinical Psychiatry 54 (suppl. 5), 69-74.
16. Cowley, D. S., Ha, E. H. & Roy-Byrne, P. P. (1997). Determinants of pharmacologic treatment failure in panic disorder. Journal of Clinical Psychiatry 58, 555-561.
17. Davidson, J. R. (2000). Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up. and predictors of outcome. Journal of Clinical Psychiatry 61 (suppl. 5), 52-56.
18. Davies, R. D., Dubovsky, S. L., Gabbert, S. & Chapman, M. (2000). Treatment resistance in anxiety disorders. Bulletin of the Menninger Clinic 64, A22-A36.
19. DuPont, R. L., Rice, D. P., Miller, L. S., Shiraki, S. S., Rowland, C. R. & Hanwood, H. J. (1996). Economic costs of anxiety disorders. Anxiety 2, 167-172.
20. Fedoroff, I. C. & Taylor, S. (2001). Psychological and pharmacological treatments of social phobia: a meta-analysis, Journal of Clinical Psychopharmacology, 21, 311-324.
21. Finch, A. E., Lambert, M. J. & Brown, G. (2000). Attacking anxiety: a naturalistic study of a multimedia self-help program. Journal of Clinical Psychology 56, 11-21.
22. Foa, E. B., Keane, T. M. & Friedman, M. J. (2000). Effective Treatments for PTSD: Practice Guidelines from the International Society for Traumatic Stress Studies. The Guilford Press: New York.
23. Gale, C. & Oakley-Browne, M. A. (2000). Anxiety disorder. British Medical Journal 321, 1204-1207.
24. Gold, M. R., Siegel, J. E., Russell, L. B. & Weinstein, M. C. (1996). Cost-effectiveness in Health and Medicine. Oxford University Press: New York.
25. Goldberg, D., Jackson, G., Gater, R., Campbell, M. & Jennett, N. (1996). The treatment of common mental disorders by a community team based in primary care: a cost-effectiveness study. Psychological Medicine 26, 487-492.
26. Goldman, H. H., Ganju, V., Drake, R. E., Gorman, P., Hogan, M., Hyde, P. S. & Morgan, O. (2001). Policy implications for implementing evidence-based practices. Psychiatric Services 52, 1591-1597.
27. Gould, R. A. & Clum, G. A. (1993). A meta-analysis of self-help treatment approaches. Clinical Psychology Review 13, 169-186.
28. Gould, R. A., Otto, M. W. & Pollack, M. H. (1995). A meta-analysis of treatment outcome for panic disorder. Clinical Psychology Review 15, 819-844.
29. Gould R. A., Otto, M. W., Pollack, M. H. & Yap, L. (1997). Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: a preliminary meta-analyis. Behavior Therapy 28, 285-305.
30. Greenberg, P. E., Sisitsky, T., Kessler, R. C., Finkelstein, S. N., Berndt, E. R., Davidson, J. R., Ballenger, J. C. & Fyer, A. J. (1999). The economic burden of anxiety disorders in the 1990s. Journal of Clinical Psychiatry 60, 427-435.
31. Hargreaves, W. A., Shumway, M., Hu, T.-W. & Cuffel, B. (1998). Cost-outcome, Methods for Mental Health. Academic Press: San Diego.
32. Hatziandreu, E. J., Brown, R. E., Revicki, D. A., Turner, R., Martindale, J., Levine, S. & Siegel, J. E. (1994). Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. Pharmaco Economics 5, 249-268.
33. Heimberg, R. G. (2001). Current status of psychotherapeutic interventions for social phobia. Journal of Clinical Psychiatry 62 (suppl. 1), 36-42.
34. Heimberg, R. G., Salzman, G., Holt, C. S. & Blendell, K. A. (1993). Cognitive behavioural treatment for social phobia: effectiveness at five year follow-up. Cognitive Therapy and Research 17, 325-339.
35. Hirth, R. A., Chernew, M. E., Miller, E., Fenderick, M. & Weissert, W. G. (2000). Willingness to pay for a Quality-adjusted Life Year: in search of a standard. Medical Decision Making 20, 332-342.
36. Hollander, E. & Cohen, L. J. (1994). The assessment and treatment of refractory anxiety. Journal of Clinical Psychiatry 55 (suppl.), 27-31.
37. Hunt, C. & Andrews, G. (1998). Long-term outcome of panic disorder and social phobia. Journal of Anxiety Disorders 12, 395-406.
38. Issakidis, C. & Andrews, G. (2002). Service utilisation for anxiety in an Australian community sample. Social Psychiatry & Psychiatric Epidemiology 37, 153-163.
39. Jenkins, R., Bebbington, P. E., Brugha, T. S., Farrell, M., Gill, B., Lewis, G., Meltzer, H. & Petticrew, M. (1997). The National Psychiatric Morbidity surveys of Great Britain - strategy and methods. Psychological Medicine 27, 765-774.
40. Kaltenthaler, E., Shackley, P., Stevens, K., Beverly, C., Parry, G. & Chilcott, J. (2002). Computerised Cognitive Behaviour Therapy for Depression and Anxiety. Report on behalf of The National Institute for Clinical Excellence: London.
41. Katzelnick, D. J., Kobak, K. A., DeLeire, T., Henk, H. J., Greist, J. H., Davidson, J. R., Schneier, F. R., Stein, M. B. & Helstad, C. P. (2001). Impact of generalized social anxiety disorder in managed care. American Journal of Psychiatric 158, 1999-2007.
42. Kessler, R. C., McGonagle, K. A., Zhao, S., Nelson, C. B., Hughes, M., Eshleman, S., Wittchen, H. U. & Kendler, K. S. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry 51, 8-19.
43. Kirsch, I. & Sapirstein, G. (1998). Listening to prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevention & Treatment 1, Article 0002a. http://journals.apa.org/prevention volume1/pre0010002a.html.
44. Lawrie, S. M., Scott, A. I. & Sharpe, M. C. (2001). Implementing evidence-based psychiatry: whose responsibility? British Journal of Psychiatry 178, 195-196.
45. Laupacis, A., Feeny, D., Detsky, A. S. & Tugwell, P. X. (1993). How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Journal of the Canadian Medical Association 148, 913-917.
46. Leon, A. C., Portera, L. & Weissman, M. M. (1995). The social costs of anxiety disorders. British Journal of Psychiatry 166, 19-22.
47. Lim, D., Sanderson, K. & Andrews, G. (2000). Lost productivity among full-time workers with mental disorders. Journal of Mental Health Policy and Economics 3, 139-146.
48. Lonnqvist, J., Sintonen, H., Syvalahti, E., Appelberg, B., Koskinen, T., Mannikko, T., Mehtonen, O. P., Naarala, M., Sihvo, S. & Auvinen, J. (1994). Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine. Acta Psychiatrica Scandinavica 89, 363-369.
49. Manderscheid, R. W., Rae, D. S., Narrow, W. E., Locke, B. Z. & Regier, D. A. (1993). Congruence of service utilization estimates from the Epidemiologic Catchment Area Project and other sources. Archives of General Psychiatry 50, 108-114.
50. Mathers, C., Vos, T. & Stevenson, C. (1999). The Burden of Disease and Injury in Australia. Australian Institute of Health and Welfare: Canberra.
51. Mason, J., Freemantle, N., Nazareth, I., Eccles, M., Haines, A. & Drummond, M. (2001). When is it cost-effective to change the behavior of health professionals? Journal of the American Medical Association 286, 2988-2992.
52. Meadows, G., Liaw, T., Burgess, P., Bobevski, I. & Fossey, E. (2001). Australian general practice and the meeting of needs for mental health care. Social Psychiatry and Psychiatric Epidemiology 36, 595-603.
53. Melse, J. M., Essink-Bot, M. L., Kramers, P. G. & Hoeymans, N. (2000). A national burden of disease calculation: Dutch disability-adjusted life-years. Dutch Burden of Disease Group. American Journal of Public Health 90, 1241-1247.
54. Mendlowicz, M. V. & Stein, M. B. (2000). Quality of life in individuals with anxiety disorders. American Journal of Psychiatry 157, 669-682.
55. Murray, C. J. L. & Lopez, A. D. (eds.) (1996). The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Harvard University Press: Cambridge. MA.
56. Murray, C. J. L., Evans, D. B., Acharya, A. & Baltussen, R. M. (2000). Development of WHO guidelines on generalized cost-effectiveness analysis. Health Economics 9, 235-251.
57. Murray, C. J. L., Salomon, J. A., Mathers, C. D. & Lopez, A. D. (eds.) (2002). Summary Measures of Population Health: Concepts, Ethics, Measurement and Applications. World Health Organization: Geneva.
58. Nathan, P. E. & Gorman, J. M. (eds.) (2002). A Guide to Treatments that Work. 2nd edn. Oxford University Press: New York.
59. Neumann, P. J., Goldie, S. J. & Weinstein, M. C. (2000). Preference-based measures in economic evaluation in health care. Annual Review of Public Health 21, 587-611.
60. Ormel, J., Von Korff, M. & Van den, B. W., Katon, W., Brilman, E. & Oldehinkel, T. (1993). Depression, anxiety and social disability show synchrony of change in primary care patients. American Journal of Public Health 83, 385-390.
61. Palisade Corporation (2001). ®ISK: Advanced Risk Analysis for Spreadsheets. Palisade Corporation: New York.
62. Patterson, T. L., Kaplan, R. M. & Jeste, D. V. (1999). Measuring the effect of treatment on quality of life in patients with schizophrenia: focus on utility based measures. CNS Drugs 12, 49-64.
63. Royal Australian and New Zealand College of Psychiatrists (2002). Clinical Practice Guidelines for Panic Disorder and Agoraphobia. RANZCP: Melbourne.
64. Rice, D. P. & Miller, L. S. (1998). Health economics and cost implications of anxiety and other mental disorders in the United States. British Journal of Psychiatry (suppl.). 4-9.
65. Salvador-Carulla, L., Segui, J., Fernandez-Cano, P. & Canet J. (1995). Costs and offset effect in panic disorders. British Journal of Psychiatry (suppl.), 23-28.
66. Sanderson, K., Andrews, G., Corry, J. & Lapsley, H. M. (2003a). Reducing the burden of affective disorders: is evidence-based health care affordable? Journal of Affective Disorders 77, 109-125.
67. Sanderson, K., Andrews, G., Corry, J. & Lapsley, H. M. (2003b). Modelling change in preference values from descriptive health status using the effect size. Quality of Life Research (in the press).
68. Schneier, F. R. (2001). Treatment of social phobia with anti-depressants. Journal of Clinical Psychiatry 62 (suppl. 1), 43-48.
69. Scholing, A. & Emmelkamp, P. M. (1996). Treatment of generalized social phobia: results at long-term follow-up. Behaviour Research and Therapy 34, 447-452.
70. Souery, D., Amsterdam, J., de Montigny, C., Lecrubier, Y., Montgomery, S., Lipp, O., Racagni, G., Zohar, J. & Mendlewicz, J. (1999). Treatment resistant depression: methodological overview and operational criteria. European Neuropsychopharmacology 9, 83-91.
71. Van Etten, M. L. & Taylor, S. (1998). Comparative efficacy of treatments for post-traumatic stress disorder: a meta-analysis. Clinical Psychology and Psychotherapy 5, 126-144.
72. Wang, P. S., Demler, O. & Kessler, R. C. (2002). Adequacy of treatment for serious mental illness in the United States. American Journal of Public Health 92, 92-98.
73. Young, A. S., Klap, R., Sherbourne, C. D. & Wells. K. B. (2001). The quality of care for depressive and anxiety disorders in the United States. Archives of General Psychiatry 58, 55-61.